MASAC Document #162
MASAC RECOMMENDATIONS ON USE OF COX-2 INHIBITORS IN PERSONS WITH BLEEDING DISORDERS
View Printer-Friendly PDF Version >>
The following recommendations were approved by the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation on April 9, 2005, and adopted by the NHF Board of Directors on June 4, 2005
Individuals with bleeding disorders may require analgesics to supplement their clotting factor treatment plan. This includes individuals with hemophilia and joint pain associated with acute hemorrhages or chronic hemophilic arthropathy, as well as women with a bleeding disorder (e.g. von Willebrand disease) who suffer menorrhagia and menstrual pain. A class of non-steroidal anti-inflammatory drugs (NSAIDs) known as cyclooxygenase-2 (COX-2) inhibitors, with similar efficacy to NSAIDs, is approved for use in arthritis and menorrhagia. Individuals with bleeding disorders and pain have used these agents with good pain relief. Although COX-2 inhibitors are not associated with platelet dysfunction in vitro, there are anecdotal reports that use of these drugs has caused clinically significant bleeding in some individuals with bleeding disorders. In addition, rofecoxib (Vioxx©), when used in a colorectal polyp prevention trial; valdecoxib (Bextra®), when used in patients undergoing coronary artery bypass grafting; and celecoxib (Celebrex®), when used in individuals to reduce development of colorectal cancer, have been associated with increased frequency of thromboembolic events, including heart attacks and strokes. These observations have led to the withdrawal of rafecoxib (Vioxxâ) and valdecoxib (Bextra®) by their manufacturer. Celecoxib (Celebrex®) remains the only COX-2 inhibitor available for patient use. Whether similar risks exist with other NSAIDS, such as ibuprofen or naproxen, and whether these risks apply to individuals with bleeding disorders is not yet established.
For these reasons, caution is advised with the use of COX-2 agents (e.g. celecoxib) in individuals with bleeding disorders. For example, thromboembolic risks seem to be greater in those individuals with active or prior coronary artery disease (myocardial infarction, unstable angina, etc.), hypertension, or stroke. The frequency of these adverse events was associated with higher than standard dosing of these medications and with their prolonged use. Therefore, providers should maintain close vigilance for symptoms and signs of heart attack, stroke, or gastrointestinal bleeding and should discuss these potential risks in the context of their potential benefits with their patients. A switch to alternative analgesics may be considered. If a COX-2 inhibitor is prescribed, it should be used at the lowest effective dose for the least necessary duration.
1. Caution is advised with use of COX-2 inhibitors in individuals with bleeding disorders. The potential risks of gastrointestinal bleeding, heart attack, and strokes should be weighed against the potential benefits.
2. Individuals sensitive to sulfa should be aware that the COX-2 inhibitor, celecoxib (Celebrex®), contains sulfa groups which may precipitate allergic reactions.
3. Research should be conducted to determine whether alternative COX-2 inhibitors not currently available, such as refecoxib (Vioxx) which does not contain sulfa, can be safely used in lower doses in individuals with bleeding disorders.
4. Special attention should be paid to the use of COX-2 inhibitors in children, in whom thromboembolic risks remain to be assessed.
This material is provided for your general information only. NHF does not give medical advice or engage in the practice of medicine. NHF under no circumstances recommends particular treatment for specific individuals and in all cases recommends that you consult your physician or local treatment center before pursuing any course of treatment.
Copyright 2003 National Hemophilia Foundation. To facilitate the dissemination of these medical recommendations, reproduction of any material in this publication in whole or in part will be permitted provided: 1) a specific reference to the MASAC recommendation number and title is included and 2) the reproduction is not intended for use in connection with the marketing, sale or promotion of any product or service. NHF reserves the right to make the final determination of compliance with this policy. For questions or to obtain a copy of the most recent recommendations, please contact the NHF Director of Communications at 1-800-42-HANDI or visit the NHF website at www.hemophilia.org.